Get the Stockscreener App
7.45
18.82%
1.18
After Hours:
7.47
0.02
+0.27%
Actuate Therapeutics Inc stock is traded at $7.45, with a volume of 51,484.
It is up +18.82% in the last 24 hours and down -7.45% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$6.27
Open:
$6.5
24h Volume:
51,484
Relative Volume:
2.46
Market Cap:
$142.38M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.86%
1M Performance:
-7.45%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.47
$7.80
1-Week Range:
$5.51
$7.80
52-Week Range:
$5.51
$10.16
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Actuate Therapeutics Inc Stock (ACTU) Latest News
Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
Actuate Announces Scientific Reports Publication on - GlobeNewswire
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor - Yahoo Finance
Achilles Therapeutics Announces Strategic Update - StockTitan
Cintas (NASDAQ:CTAS) PT Raised to $225.00 - Defense World
Cintas (NASDAQ:CTAS) PT Raised to $225.00 at Truist Financial - MarketBeat
Capricor rises as it expands deal with Nippon Shinyaku - The Pharma Letter
Capricor Therapeutics Secures Lucrative European Partnership - TipRanks
Capricor Therapeutics Signs Binding Term Sheet with Nippon - GlobeNewswire
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - StockTitan
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga
Actuate Announces Upcoming Presentation on Initial Data on - GlobeNewswire
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Behind the Bell: Actuate Therapeutics - Nasdaq
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas - GlobeNewswire
Actuate gains FDA orphan drug status for cancer treatment - Investing.com
Biopharma financings near $78B, almost double last year’s value - BioWorld Online
Elraglusib shows promise in Ewing sarcoma trial - Investing.com
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - GlobeNewswire
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - GlobeNewswire Inc.
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Actuate Therapeutics (NASDAQ:ACTU) Stock Quotes, Forecast and News Summary - Benzinga
Actuate Therapeutics’ $22,4 Million Initial Public Offering - Global Legal Chronicle
Actuate Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Actuate Therapeutics Rings the Opening Bell - Nasdaq
Wheeling Native Daniel Schmitt To Ring Wall Street Bell - Wheeling Intelligencer
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 - GlobeNewswire
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 - StockTitan
Actuate Therapeutics appoints new accounting firm By Investing.com - Investing.com Australia
Actuate Therapeutics appoints new accounting firm - Investing.com India
Actuate Therapeutics appoints new accounting firm - Investing.com
Actuate Therapeutics appoints new accounting firm By Investing.com - Investing.com UK
IPO Roundup: WeRide, Reitar Logtech and more (NYSEARCA:IPO) - Seeking Alpha
Todd S. Thomson Sells 18,750 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Opening Day: Actuate Therapeutics makes public debut - TipRanks
Actuate therapeutics insider sells $150,000 worth of shares By Investing.com - Investing.com Australia
Actuate therapeutics insider sells $150,000 worth of shares By Investing.com - Investing.com Canada
Actuate therapeutics insider sells $150,000 worth of shares - Investing.com
Items Tagged with 'glycogen synthase kinase-3 inhibitor' - BioWorld Online
Biopharma IPO volume at 10-year low; Actuate raises $22.4M - BioWorld Online
Leslie W. Kreis Sells 24,999 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Director Equity Cof Lp Bios Purchases 500,000 Shares - Defense World
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com UK
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com Australia
Actuate Therapeutics insiders buy $4m in stock, sell $234k By Investing.com - Investing.com South Africa
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com Canada
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com India
Actuate Therapeutics insiders execute stock transactions worth over $4m By Investing.com - Investing.com South Africa
Actuate Therapeutics insiders execute stock transactions worth over $4m By Investing.com - Investing.com Australia
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):